highgrade serous carcinoma hgsc type tumour arises serous epithelial layer abdominopelvic cavity mainly found ovary hgscs make majority ovarian cancer lowest survival hgsc distinct lowgrade serous carcinoma lgsc arises ovarian tissue less aggressive present stage ovarian cancer tumours localised ovary although originally thought arise squamous epithelial cell layer covering ovary hgsc thought originate fallopian tube epithelium hgsc much invasive lgsc higher fatality rate although sensitive platinumbased possibly due rapid growth rate rare cases hgscs develop generally two types arise independently incessant ovulation theory suggested strong correlation number ovulatory cycles individual risk ovarian trend reflected protective effects pregnancy parity breastfeeding ovarian similar findings epidemiological studies indicated reduction risk associated use oral contraceptive ovulation accepted cause ovarian cortical inclusion cysts precursor lesions serous carcinomas lower numbers cortical inclusion cysts thought mechanism reducing lifetime ovulations lower risk developing conversely temporal association menopausal hormone therapy incidence hgsc polycystic ovarian syndrome pcos shown contribute doubling risk ovarian endometriosis increase risk ovarian cancer subtypes associated ovarian cancer tumours hereditary origin majority feature mutations tumour suppressor brca genes tend give rise mutation confer lifetime ovarian cancer risk mutations strongly associated better clinical outcomes specific tumour protein expression pattern fallopian tube epithelium signature thought precursor marker hgsc mice gene deleted develop ovarian however mutations found hgsc local abnormal expression may thus indicative women pelvic hgsc show either complete absence expression overexpression suggesting aberration leads tumour additionally overexpression associated better clinical outcome whereas absence protein linked increased risk hgsc tumour recent mouse model suggest mutation may induce hgsc arising ovary rather fallopian hgsc distinguished lgsc type iii ovarian tumour type referring tumour types eg lgscs precursor lesions within ovary characterised type ii referring tumour types eg hgscs without association lesions tumours understood develop de novo tubal andor ovarian surface epithelium classification relevance research rather clinical serous membrane particular type secretory epithelium covers organs body cavities secretes serous fluid reduce friction muscle movement serous membrane lining abdominopelvic cavity called peritoneum lining heart mediastinum pericardium lining thoracic cavity lungs pleura technically serous carcinoma occur anywhere membranes highgrade serous carcinoma generally limited peritoneal area recently hgsc thought arise simple differentiation cortical inclusion cysts cics ovarian surface epithelium ose cell origin hgsc understood much complex evidence sites origin intra extraovarian come light opposing coelomic hypothesis opposing opposing supporting opposing opposing common m√ºllerian origin fallopian tubes uterus cervix upper vagina resulted proposal peritoneal highgrade serous carcinoma spectrum single relevant animal models hgsc developed cell origin properly understood however hgsc tends clinical behaviour regardless primary cell origin determining cell origin less important clinical treatment may relevance looking biomarkers specific process hgsc arises may related brca mutation status well mutation paper describes process determining cell origin tumour origin typically assigned organ presenting dominant tumour mass one exception peritoneum classified primary site candidate origin found endometrium tube ovary recognised hgsc variable complex primary origins understanding determining give insight pathogenesis assuming fimbrial origin observed majority hgsc current understanding hgsc genesis suggests process stic fimbrial cells implant ovary cortical inclusion cysts ovulation rupture site account instances stic involvement endosalpingiosis de novo metaplasia ovarian surface epithelium inclusions also possible much rarer occurrence differentiation hgsc symptoms include persistent bloating postmenopausal bleeding andor appetite transvaginal ultrasonography well cancer marker level analysis often used determine potential malignancy suspect pelvic surgical staging procedure abdominal cavity lymph nodes examined malignant tissue usually via laparoscopy tissue biopsies may taken analysis histological analysis stage actual diagnosis hgsc glands seen fuse intricate extensive papillae featuring epithelial tufting solid nests surrounded space alongside irregular slitlike spaces serous carcinoma suspected distinguishing lgsc distinction hgsc highgrade endometrioid carcinoma always progression hgsc may also determined examining cadherin expression ovarian cancer rarely symptomatic advanced regular preemptive screening particularly important tool avoiding late stage patients present however us study found transvaginal ultrasound cancer marker screening reduce ovarian cancer contrast recent uk study found ovarian cancer deaths could prevented annual performance prevention individual deemed risk hgsc recently bilateral unilateral removal ovary fallopian tube salpingooophorectomy hormonal even morbidity issues resulting ovary removal increased evidence role fallopian tubes hgsc pathogenesis optimisation procedure remove fallopian tubes salpingectomy ovaries remaining age menopause although critics argue reduced blood supply ovaries may induce premature menopause prophylactic salpingooophorectomy frequently performed carriers although benefits conferred procedure may vary dependent specific tubal ligation less invasive prophylactic treatment shown significantly reduce risk cytoreductive debulking surgery may performed prior chemotherapy treatment order decrease physical mass tumour thus reduce number chemotherapy cycles typical advanced presentation well extraovarian spread seen hgsc require aggressive debulking cases total abdominal hysterectomy performed cases patient intends bear children salpingooophorectomy performed instead typical chemotherapy six cycles intraperitoneallydelivered platinumbase adjuvant chemotherapy agents measurements blood levels used determine patient response treatment patients relapse within six months poly adp ribose polymerase parp inhibitors another possible treatment carriers mutations responsive study incidence rates us found agespecific incidence rate hgsc doubles every years age plateaus approximately cases per women dropping dramatically age ovarian cancer incidence rates low east highest europe united states australianew since survival rates ovarian cancer steadily improved mean decrease risk death ovarian cancer advanced stage increase mainly due successful extended life expectancy affected patients rather improvement cure rates racial disparity exists black white women us black women experience higher mortality risk ovarian httpsenwikipediaorgwikihighgradeserouscarcinoma